BNOEF: AI 评分 56/100 — AI 分析 (4月 2026)

Bionomics Limited is a clinical-stage biopharmaceutical company focused on discovering and developing novel drug candidates for central nervous system disorders and cancers. Their lead drug candidate, BNC210, is currently in Phase 2 clinical trials for social anxiety disorder and Phase 2b for post-traumatic stress disorder.

Key Facts: AI Score: 56/100 Sector: Healthcare

公司概况

概要：

Bionomics Limited, an Australian clinical-stage biopharmaceutical company, specializes in developing novel treatments for central nervous system disorders and cancers, with a focus on its lead drug candidate BNC210 targeting social anxiety and PTSD, positioning it within the competitive biotechnology landscape.

BNOEF是做什么的？

Bionomics Limited, founded in 1996 and based in Eastwood, Australia, is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative drug candidates. The company focuses on addressing unmet needs in the treatment of central nervous system (CNS) disorders and cancers. Bionomics' lead drug candidate, BNC210, a negative allosteric modulator of the α7 nicotinic acetylcholine receptor, is currently undergoing Phase 2 clinical trials for social anxiety disorder (SAD) and Phase 2b trials for post-traumatic stress disorder (PTSD). This drug represents a core element of their pipeline, targeting significant mental health conditions. In addition to BNC210, Bionomics is developing BNC101, a monoclonal antibody targeting cancer stem cells, which has completed Phase 1 clinical trials. The company also has BNC105, in Phase 2 clinical trials for refractory colorectal cancer and Phase 1 for relapsed/refractory chronic lymphocytic leukemia. Bionomics operates primarily in the biotechnology sector, focusing on drug discovery and clinical development. The company aims to create value through the successful development and commercialization of its drug candidates, addressing critical needs in both CNS disorders and oncology.

BNOEF的投资论点是什么？

Bionomics Limited presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biopharmaceutical companies. The primary value driver is the successful clinical development and potential commercialization of BNC210 for social anxiety disorder and post-traumatic stress disorder. Positive Phase 2 and Phase 2b trial results could serve as significant catalysts, potentially leading to partnerships or acquisition. However, the company's negative profit margin of -4546.6% and reliance on future clinical trial success present substantial risks. The company's market capitalization is $0.01 billion as of March 18, 2026. Investors should carefully weigh the potential upside against the inherent uncertainties of drug development and regulatory approval.

BNOEF在哪个行业运营？

Bionomics Limited operates within the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful drug candidates. The company focuses on CNS disorders and oncology, areas with substantial unmet needs and growing market demand. The biotechnology industry is driven by innovation and technological advancements, with companies constantly seeking to develop novel therapies and improve patient outcomes. Bionomics faces competition from larger pharmaceutical companies and other biotechnology firms developing treatments for similar indications.

Biotechnology

Healthcare

BNOEF有哪些增长机遇？

BNC210 for Social Anxiety Disorder (SAD): The market for SAD treatments is substantial, with millions affected globally. Successful Phase 2 trial results and subsequent commercialization of BNC210 could generate significant revenue for Bionomics. The timeline for potential market entry depends on clinical trial outcomes and regulatory approvals, but could be within the next 3-5 years. Bionomics' competitive advantage lies in the novel mechanism of action of BNC210.
BNC210 for Post-Traumatic Stress Disorder (PTSD): PTSD represents another significant market opportunity, with a growing awareness of the condition and increasing demand for effective treatments. Positive Phase 2b trial results for BNC210 in PTSD could lead to accelerated development and commercialization. The timeline is similar to SAD, contingent on clinical trial success and regulatory pathways. Bionomics aims to address the limitations of existing PTSD treatments with BNC210.
BNC101 for Cancer Stem Cells: Targeting cancer stem cells represents a novel approach to cancer treatment, with the potential to improve outcomes and reduce recurrence rates. Bionomics' BNC101, a monoclonal antibody, has completed Phase 1 clinical trials. Further development and clinical validation could open up significant opportunities in the oncology market. The timeline for commercialization is longer, potentially 5-7 years, due to the early stage of development.
BNC105 for Refractory Colorectal Cancer: Colorectal cancer remains a leading cause of cancer-related deaths, and refractory cases present a significant challenge. Bionomics' BNC105 is in Phase 2 clinical trials for this indication. Positive results could lead to regulatory approval and market access. The timeline for potential commercialization is approximately 3-5 years, depending on clinical trial outcomes and regulatory review.
Partnerships and Licensing Agreements: Bionomics can leverage its drug candidates and technology platform to establish partnerships and licensing agreements with larger pharmaceutical companies. These collaborations can provide funding for further development and commercialization, while also expanding the reach of Bionomics' products. The timing and value of such agreements are uncertain, but they represent a significant growth opportunity for the company.

Market capitalization of $0.01 billion, reflecting its small-cap status within the biotechnology sector.
Negative P/E ratio of -0.06, indicative of current losses and the company's investment in research and development.
Gross margin of 94.7%, suggesting strong potential profitability if drug candidates reach commercialization.
Profit margin of -4546.6%, highlighting the significant expenses associated with clinical trials and drug development.
Beta of 1.84, indicating higher volatility compared to the overall market, typical for biotechnology companies.

BNOEF提供哪些产品和服务？

Discovers novel drug candidates for central nervous system disorders and cancers.
Develops BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor.
Conducts Phase 2 clinical trials for BNC210 in social anxiety disorder.
Conducts Phase 2b clinical trials for BNC210 in post-traumatic stress disorder.
Develops BNC101, a monoclonal antibody targeting cancer stem cells.
Conducts Phase 1 clinical trials for BNC101.
Develops BNC105 for the treatment of refractory colorectal cancer and relapsed/refractory chronic lymphocytic leukemia.

BNOEF如何赚钱？

Focuses on research and development of novel drug candidates.
Out-licenses or partners with larger pharmaceutical companies for commercialization.
Generates revenue through milestone payments and royalties from partnered programs.

Pharmaceutical companies seeking to in-license or acquire novel drug candidates.
Patients suffering from central nervous system disorders and cancers.
Healthcare providers prescribing medications to treat these conditions.

Proprietary drug candidates with novel mechanisms of action.
Intellectual property protection through patents and other forms of exclusivity.
Clinical data supporting the safety and efficacy of its drug candidates.

什么因素可能推动BNOEF股价上涨？

Upcoming: Release of Phase 2 clinical trial results for BNC210 in social anxiety disorder.
Upcoming: Initiation of Phase 3 clinical trials for BNC210, contingent on Phase 2 success.
Ongoing: Enrollment and progress in Phase 2b clinical trials for BNC210 in post-traumatic stress disorder.
Ongoing: Development and advancement of BNC101 and BNC105 through clinical trials.
Potential: Announcement of partnerships or licensing agreements with larger pharmaceutical companies.

BNOEF的主要风险是什么？

Potential: Failure to obtain regulatory approval for its drug candidates.
Potential: Competition from other companies developing treatments for similar indications.
Ongoing: Dependence on external funding to support clinical trials and operations.
Ongoing: High cash burn rate and potential need for additional financing.
Potential: Product liability claims and other legal challenges.

BNOEF的核心优势是什么？

Novel drug candidates targeting unmet medical needs.
Clinical-stage pipeline with multiple ongoing trials.
Experienced management team with expertise in drug development.
Strong intellectual property portfolio.

BNOEF的劣势是什么？

Limited financial resources and reliance on external funding.
High risk of clinical trial failure.
Dependence on successful commercialization of a limited number of drug candidates.
OTC market listing.

BNOEF有哪些机遇？

Successful clinical trial results leading to regulatory approval.
Partnerships and licensing agreements with larger pharmaceutical companies.
Expansion of pipeline through internal discovery and external acquisitions.
Growing market demand for effective treatments for CNS disorders and cancers.

BNOEF面临哪些威胁？

Competition from larger pharmaceutical companies with greater resources.
Regulatory hurdles and delays in drug approval processes.
Unfavorable changes in healthcare policies and reimbursement rates.
Product liability claims and other legal challenges.

BNOEF的竞争对手是谁？

Eiger BioPharmaceuticals Inc. — Focuses on developing therapies for serious diseases with limited or no treatment options. — (EIGRQ)
Flow Pharma Inc. — Develops targeted drug delivery systems. — (FLWPF)
Forward Pharma A/S — Focuses on developing and commercializing innovative therapies. — (FWPAY)
Hope Biosciences Inc. — Develops cell-based therapeutics and regenerative medicine products. — (HBCNF)
ImunOnco Inc. — Develops novel immunotherapies for cancer treatment. — (IMUN)

Key Metrics

MoonshotScore: 56/100

Company Profile

CEO: Spyridon Papapetropoulos
Headquarters: Eastwood, AU
Founded: 2014

AI Insight

AI analysis pending for BNOEF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Bionomics Limited do?

Bionomics Limited is a clinical-stage biopharmaceutical company focused on discovering and developing novel drug candidates for the treatment of central nervous system (CNS) disorders and cancers. Their lead drug candidate, BNC210, is a negative allosteric modulator of the α7 nicotinic acetylcholine receptor and is currently in Phase 2 clinical trials for social anxiety disorder and Phase 2b trials for post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody targeting cancer stem cells, and BNC105, which is in Phase 2 clinical trials for refractory colorectal cancer and Phase 1 for relapsed/refractory chronic lymphocytic leukemia. Bionomics aims to address unmet medical needs in these therapeutic areas through innovative drug development.

What do analysts say about BNOEF stock?

As of March 18, 2026, there is no readily available analyst consensus on BNOEF stock, likely due to its OTC listing and small market capitalization. Key valuation metrics such as P/E ratio (-0.06) and profit margin (-4546.6%) reflect the company's current losses and investment in research and development. Growth considerations center on the successful clinical development and potential commercialization of BNC210 and other drug candidates. Investors should conduct their own thorough due diligence and consider the inherent risks associated with clinical-stage biotechnology companies.

What are the main risks for BNOEF?

The main risks for Bionomics Limited include the inherent uncertainties of clinical drug development, such as the risk of clinical trial failure and regulatory hurdles. The company's limited financial resources and reliance on external funding also pose a significant risk. Competition from larger pharmaceutical companies with greater resources is another factor. Additionally, BNOEF's OTC market listing introduces risks related to liquidity, price volatility, and disclosure requirements. Investors should carefully consider these risks before investing in Bionomics Limited.